S
Shashank Ganatra
Researcher at Texas Biomedical Research Institute
Publications - 25
Citations - 708
Shashank Ganatra is an academic researcher from Texas Biomedical Research Institute. The author has contributed to research in topics: Tuberculosis & Bedaquiline. The author has an hindex of 11, co-authored 21 publications receiving 456 citations. Previous affiliations of Shashank Ganatra include Tulane University.
Papers
More filters
Journal ArticleDOI
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study
Sergey Borisov,Keertan Dheda,Martin Enwerem,Rodolfo Romero Leyet,Lia D'Ambrosio,Rosella Centis,Giovanni Sotgiu,Simon Tiberi,Simon Tiberi,Jan-Willem C. Alffenaar,Andrey Maryandyshev,Evgeny Belilovski,Shashank Ganatra,Alena Skrahina,Onno W. Akkerman,Alena Aleksa,Rohit Amale,Janina Artsukevich,Judith Bruchfeld,Jose A. Caminero,Isabel Carpena Martinez,Luigi Codecasa,Margareth Pretti Dalcolmo,Justin T Denholm,Paul Douglas,Raquel Duarte,Aliasgar Esmail,Mohammed Fadul,Alexey Filippov,Lina Davies Forsman,Mina Gaga,Julia Amaranta Garcia-Fuertes,José-María García-García,Gina Gualano,Jerker Jonsson,Heinke Kunst,Jillian S.Y. Lau,Barbara Lazaro Mastrapa,Jorge Lazaro Teran Troya,Selene Manga,Katerina Manika,Pablo González Montaner,Jai B Mullerpattan,Suzette Oelofse,Martina Ortelli,Domingo Palmero,Fabrizio Palmieri,Antonella Papalia,Apostolos Papavasileiou,Marie-Christine Payen,Emanuele Pontali,Carlos Robalo Cordeiro,Laura Saderi,Tsetan Dorji Sadutshang,Tatsiana Sanukevich,Varvara Solodovnikova,Antonio Spanevello,Sonam Topgyal,Federica Toscanini,Adrian R Tramontana,Zarir F Udwadia,Pietro Viggiani,Veronica White,Alimuddin Zumla,Giovanni Battista Migliori +64 more
TL;DR: Bedaquiline-containing regimens achieved high conversion and success rates under different nonexperimental conditions, and is safe and effective in treating MDR- and XDR-TB patients.
Journal ArticleDOI
Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets.
Dhiraj Kumar Singh,Bindu Singh,Shashank Ganatra,Michal Gazi,Journey Cole,Rajesh Thippeshappa,Kendra J. Alfson,Elizabeth Clemmons,Olga Gonzalez,Ruby Escobedo,Tae-Hyung Lee,Ayan Chatterjee,Yenny Goez-Gazi,Riti Sharan,Maya Gough,Cynthia Alvarez,Alyssa Blakley,Justin Ferdin,Carmen Bartley,Hilary M. Staples,Laura M. Parodi,Jessica Callery,Amanda Mannino,Benjamin Klaffke,Priscilla Escareno,Roy N. Platt,Vida L. Hodara,Julia M. Scordo,Shalini Gautam,Andreu G. Vilanova,Angélica Olmo-Fontánez,Alyssa Schami,Adelekan Oyejide,Dharani Ajithdoss,Richard Copin,Alina Baum,Christos A. Kyratsous,Xavier Alvarez,Mushtaq Ahmed,Bruce A. Rosa,Anna Goodroe,John Dutton,Shannan Hall-Ursone,Patrice A. Frost,Andra K. Voges,Andra K. Voges,Corinna N. Ross,Ken Sayers,Christopher H. Chen,Cory R. A. Hallam,Shabaana A. Khader,Makedonka Mitreva,Tim J. Anderson,Luis Martinez-Sobrido,Jean L. Patterson,Joanne Turner,Jordi B. Torrelles,Edward J. Dick,Kathleen M. Brasky,Larry S. Schlesinger,Luis D. Giavedoni,Ricardo Carrion,Deepak Kaushal +62 more
TL;DR: In this paper, the authors compared acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in young and old rhesus macaques, baboons and old marmosets.
Journal ArticleDOI
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
Andrey Maryandyshev,Emanuele Pontali,Simon Tiberi,Onno W. Akkerman,Shashank Ganatra,Tsetan Dorji Sadutshang,Jan-Willem C. Alffenaar,Rohit Amale,Jai B Mullerpattan,Sonam Topgyal,Zarir F Udwadia,Rosella Centis,Lia D'Ambrosio,Giovanni Sotgiu,Giovanni Battista Migliori +14 more
TL;DR: Use of bedaquiline with delamanid in combination with QT-interval prolongation is justified for patients with limited options.
Journal ArticleDOI
Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment
Uma Shanmugasundaram,Allison N. Bucsan,Shashank Ganatra,Shashank Ganatra,Chris C. Ibegbu,Chris C. Ibegbu,Melanie Quezada,Robert V Blair,Xavier Alvarez,Vijayakumar Velu,Vijayakumar Velu,Deepak Kaushal,Deepak Kaushal,Jyothi Rengarajan,Jyothi Rengarajan +14 more
TL;DR: Mycobacterium tuberculosis (Mtb)-specific T cell responses associated with immune control during asymptomatic latent tuberculosis infection (LTBI) remain poorly understood but are relevant for developing better strategies to control TB.
Journal ArticleDOI
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study
Onno W. Akkerman,Alena Aleksa,Jan-Willem C. Alffenaar,Nada Hassan Al-Marzouqi,Miguel Arias-Guillén,Evgeny Belilovski,Enrique Bernal,Martin J. Boeree,Sergey Borisov,Judith Bruchfeld,Julen Cadiñanos Loidi,Qingshan Cai,Jose A. Caminero,Jose Joaquin Cebrian Gallardo,Rosella Centis,Luigi Codecasa,Lia D'Ambrosio,Margareth Pretti Dalcolmo,Edvardas Danila,Masoud Dara,Edita Davidavičienė,Lina Davies Forsman,Jorge De Los Rios Jefe,Justin T Denholm,Raquel Duarte,Seifeldin Eltaeb Elamin,Maurizio Ferrarese,Alexey Filippov,Shashank Ganatra,Ana Garcia,José-María García-García,Regina Gayoso,Ángela María Giraldo Montoya,R. Rosso,Gina Gualano,Wouter Hoefsloot,Biljana Ilievska-Poposka,Jerker Jonsson,Elena Khimova,Liga Kuksa,Heinke Kunst,Rafael Laniado-Laborín,Yang Li,Cecile Magis-Escurra,Vinicio Manfrin,Selene Manga,Valentina Marchese,Elena Martínez Robles,Andrei Maryandyshev,Alberto Matteelli,Giovanni Battista Migliori,Jai B Mullerpattan,Marcela Muñoz-Torrico,Hamdan Mustafa Hamdan,Magnolia Nieto Marcos,Noorliza Mohamad Noordin,Domingo Palmero,Fabrizio Palmieri,Marie-Christine Payen,Alberto Piubello,Emanuele Pontali,Agostina Pontarelli,Sarai Quirós,Adrian Rendon,Alena Skrahina,Agnese Šmite,Ivan Solovic,Giovanni Sotgiu,Mahamadou Bassirou Souleymane,Antonio Spanevello,Maja Stošić,Marina Tadolini,Simon Tiberi,Zarir F Udwadia,Martin van den Boom,Marisa Vescovo,Pietro Viggiani,Dina Visca,Dmitry Zhurkin,Matteo Zignol,adverse events monitoring +80 more
TL;DR: The aim of the a DSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs.